MX2022000570A - Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad. - Google Patents

Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad.

Info

Publication number
MX2022000570A
MX2022000570A MX2022000570A MX2022000570A MX2022000570A MX 2022000570 A MX2022000570 A MX 2022000570A MX 2022000570 A MX2022000570 A MX 2022000570A MX 2022000570 A MX2022000570 A MX 2022000570A MX 2022000570 A MX2022000570 A MX 2022000570A
Authority
MX
Mexico
Prior art keywords
disease
disorder
liver
inflammation
cirrhosis
Prior art date
Application number
MX2022000570A
Other languages
English (en)
Inventor
Daniela Carmen Oniciu
Original Assignee
Espervita Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Espervita Therapeutics Inc filed Critical Espervita Therapeutics Inc
Publication of MX2022000570A publication Critical patent/MX2022000570A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/34—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings containing more than one carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/39—Unsaturated compounds containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Abstract

La presente invención proporciona compuestos de las fórmulas (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA) y (IIIB); sus sales y solvatos farmacéuticamente aceptables; y sus composiciones. La presente invención también proporciona métodos para tratar una enfermedad, incluyendo, pero sin limitación, enfermedad hepática o una condición hepática anormal; cáncer (tales como carcinoma hepatocelular o colangiocarcinoma); un tumor maligno o benigno del pulmón, hígado, vejiga biliar, conductos biliares o tracto digestivo; una enfermedad de los conductos biliares intra- o extrahepática; un trastorno de lipoproteína; un trastorno lipídico y metabólico; cirrosis; fibrosis; una enfermedad del metabolismo de glucosa; un trastorno cardiovascular o vascular relacionado; una enfermedad resultante de esteatosis, fibrosis o cirrosis; una enfermedad asociada con mayor inflamación (tales como inflamación hepática o inflamación pulmonar); balonización de los hepatocitos; un trastorno asociado con el receptor activado por el proliferador de peroxisoma; un trastorno de ATP citrato liasa; un trastorno de la acetil-coenzima A carboxilasa; obesidad; pancreatitis; o enfermedad renal.
MX2022000570A 2019-07-26 2020-07-23 Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad. MX2022000570A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878852P 2019-07-26 2019-07-26
US201962901739P 2019-09-17 2019-09-17
PCT/US2020/043274 WO2021021563A1 (en) 2019-07-26 2020-07-23 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease

Publications (1)

Publication Number Publication Date
MX2022000570A true MX2022000570A (es) 2022-03-11

Family

ID=74189909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000570A MX2022000570A (es) 2019-07-26 2020-07-23 Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad.

Country Status (12)

Country Link
US (6) US11098002B2 (es)
EP (1) EP4003314A4 (es)
JP (1) JP2022542238A (es)
KR (1) KR20220039754A (es)
CN (1) CN114126593A (es)
AU (1) AU2020321945A1 (es)
BR (1) BR112022000993A2 (es)
CA (1) CA3143294A1 (es)
IL (1) IL289919A (es)
MX (1) MX2022000570A (es)
TW (1) TW202118750A (es)
WO (1) WO2021021563A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008567A (es) 2021-01-25 2023-08-28 Espervita Therapeutics Inc Acidos monocarboxilicos y dicarboxilicos de hidrocarburos de cadena larga funcionalizados y derivados de estos, y su uso para la prevencion o el tratamiento de enfermedades.
US11730712B2 (en) 2021-01-25 2023-08-22 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
EP4297872A1 (en) * 2021-02-26 2024-01-03 OBI Pharma, Inc. Use of akr1c3-activated compound
CN115887435A (zh) * 2021-09-23 2023-04-04 博骥源（上海）生物医药有限公司 长链类化合物及其用途
CN114736191B (zh) * 2022-04-01 2023-08-08 上海工程技术大学 特普替尼中间体及其制备方法和应用
CN114949230A (zh) * 2022-06-13 2022-08-30 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN115844887B (zh) * 2022-12-28 2023-09-08 中国人民解放军空军军医大学 Selonsertib在制备治疗癌症的药物中的用途
CN117843938A (zh) * 2024-03-08 2024-04-09 华东理工大学 一种类聚烯烃的长碳链聚酯弹性体、制备方法及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US397037A (en) 1889-01-29 Conductor-support
US2789970A (en) 1953-12-08 1957-04-23 Eastman Kodak Co Polycarbonates from 1, 4-bis-(beta-hydroxyethyl)-benzenes-bis
GB900875A (en) 1959-11-12 1962-07-11 Sierra Eng Co Check valve
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2410782C2 (de) 1974-03-07 1982-02-18 Dynamit Nobel Ag, 5210 Troisdorf Phenylendiessigsäuredialkylester und Verfahren zu deren Herstellung
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5387672A (en) * 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE384035T1 (de) 1999-04-01 2008-02-15 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
JP2004511453A (ja) 2000-10-11 2004-04-15 エスペリオン　セラピューティクス，インコーポレイテッド コレステロールの制御及び関連する使用のためのケトン化合物及び組成物
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス，インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
EP1497247A2 (en) * 2002-04-10 2005-01-19 Esperion Therapeutics Inc. Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses
MXPA05007674A (es) 2003-01-23 2005-09-22 Esperion Therapeutics Inc Compuestos de hidroxilo y composiciones para el manejo del colesterol y usos relacionados.
WO2012054535A2 (en) 2010-10-18 2012-04-26 Cerenis Therapeutics Sa Compounds, compositions and methods useful for cholesterol mobilisation
SG10201912713YA (en) 2014-11-14 2020-02-27 Gemphire Therapeutics Inc PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
CN105801405A (zh) 2016-05-23 2016-07-27 天津迪尔斯化学科技有限公司 一种降血脂小分子化合物、中间体及各自制备方法

Also Published As

Publication number Publication date
US20210024447A1 (en) 2021-01-28
KR20220039754A (ko) 2022-03-29
EP4003314A1 (en) 2022-06-01
US20210269384A1 (en) 2021-09-02
JP2022542238A (ja) 2022-09-30
WO2021021563A1 (en) 2021-02-04
CA3143294A1 (en) 2021-02-04
US20240092721A1 (en) 2024-03-21
US20220402851A1 (en) 2022-12-22
BR112022000993A2 (pt) 2022-06-07
US11267778B2 (en) 2022-03-08
US11084773B1 (en) 2021-08-10
US11098002B2 (en) 2021-08-24
US20230007838A1 (en) 2023-01-12
TW202118750A (zh) 2021-05-16
CN114126593A (zh) 2022-03-01
US20210221765A1 (en) 2021-07-22
AU2020321945A1 (en) 2022-01-20
IL289919A (en) 2022-03-01
EP4003314A4 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
MX2022000570A (es) Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad.
Park et al. Intraductal papillary neoplasm of the bile duct: clinical, imaging, and pathologic features
Manfredi et al. Magnetic resonance imaging of cholangiocarcinoma
Koglin et al. Specific PET imaging of xC− transporter activity using a 18F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism
MX2021006034A (es) Agonistas de glp-ir y usos de los mismos.
Nishikawa et al. Clinical significance of therapy using branched‐chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma
Ohshima et al. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma
JP2014520823A5 (es)
Wu et al. Functional role of peroxisome‐proliferator‐activated receptor γ in hepatocellular carcinoma
BR112021022431A2 (pt) Moduladores de molécula pequena de metabolismo bacteriano intestinal do ácido biliar
Hermida et al. Small steatotic HCC: a radiological variant associated with improved outcome after ablation
Lin et al. NAFLD aggravates acute pancreatitis through bacterial translocation and cholesterol metabolic dysregulation in the liver and pancreas in mice
Shah et al. Intrahepatic cholangiocarcinoma masquerading as liver abscess
MX2022010548A (es) Agonistas de gpr40.
Katsiki et al. Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice?
Weimann et al. Is liver transplantation superior to resection in early stage hepatocellular carcinoma?
Belghiti Transplantation for liver tumors
Akhilandeswari et al. Variations in the source of origin of inferior phrenic artery: a cadaveric study
Siriratnam et al. Pulmonary tumour thrombotic microangiopathy: a rare but underappreciated complication of malignancy.
Altonbary et al. Endoscopic ultrasound-guided choledechoduodenostomy for palliative biliary drainage of obstructing pancreatic head mass
Binmoeller et al. Mo1451 “Underwater” ampullectomy for benign adenomas: prospective study of a novel technique
Tae-Seok et al. The outcomes of hepatic resection for HCC with portal vein tumor thrombosis: A multicenter study in South Korea
Kerdput et al. Beneficial and adverse effects of sorafenib drug on hepatocellular carcinoma-bearing rats: morphological and molecular evidences
Lebowitz 40 Extrahepatic collateral arterial supply to hepatocellular carcinoma
Iwaki et al. Mass-forming intrahepatic cholangiocarcinoma with portal vein tumor thrombus and bile duct tumor thrombus: a case report